NASDAQ NMS - GLOBAL MARKET · DXR
-0.48% · -$0.0500 · Vol 7.5K
Market closed · last close 4:00 PM ET · price as of 16:00:00 ET
Daxor Corp

Daxor Corp

Health Care
$10.41
Card
Relationship Map

Follow $DXR

One email when a member of Congress discloses a trade in it, with the official filing receipt linked.

Free. No account. Unsubscribe in one click.

Follow $DXR by email

Veridion Score

BETAMEDIUM CONF · 6 of 6 factors measuredMethodology
DXR
Daxor Corp
Fri Oct 9 · last completed session · Markets closed · resumes Mon 9:30 ET
Upper range

Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

71/ 100
Veridion Score
Upper range · MEDIUM confidence · 6 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: MEDIUM · 6 of 6 factors measured · Fri Oct 9 · last completed session · Markets closed · resumes Mon 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is DXR moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading DXR catalysts
About Daxor Corp
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Listed since
1983
Employees
750
Country
US

Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA offers unmatched, real-time, precise data via its rapid, hand-held, lab-based system. The company operates as a single business segment centered on the development, commercialization, and support of its proprietary blood volume analysis technology used by healthcare providers.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$10.51
Day high
$10.71
Day low
$10.41
Previous close
$10.46
52W high
$14.75
-29.42% from high
52W low
$8.87
26% of range
Market cap
$61.1M
P/E
10.12×
EPS
$1.52
Beta
0.76
Shares out
5.8M
Volume
7.5K
0.21× rel vol
Avg volume
34.9K
VWAP
$10.53
Price history computed in-house
1W
-1.98%
1M
-3.97%
3M
-1.14%
1Y
-17.45%
YTD
-29.42%
SMA 50 $10.67 · below
SMA 200 $11.16 · below
52W position 26%

DXR overview

Veridion Score
71
Registered · 2026-10-09
6 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around DXR.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading DXR Form 4 filings
Public disclosures

Congress activity in DXR

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified filings found.

Federal contracts

DXR contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for DXR in this window.
Lobbying spend

DXR lobbying filings, year to date.

Registered lobbying filings matched to Daxor Corp.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for DXR in this window.
Loading news for DXR
Analyst ratings
Sovereign unlock shows live analyst consensus for DXR.
Options
Options data is temporarily unavailable. Changing your plan will not restore the upstream feed.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.